[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer
2023年8月23日 - 2:22PM
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update
on Phase III Skyscraper-01 study in PD-L1-high metastatic non-small
cell lung cancer
Basel, 23 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY)
announced today that it has been made aware of an inadvertent
disclosure of the second interim analysis of the Phase III
SKYSCRAPER-01 study, evaluating the investigational anti-TIGIT
immunotherapy tiragolumab plus Tecentriq® (atezolizumab) versus
Tecentriq alone as an initial (first-line) treatment for people
with PD-L1-high locally advanced or metastatic non-small cell lung
cancer (NSCLC).
SKYSCRAPER-01 is ongoing and the study remains blinded to
patients and investigators. We are continuing the study until the
final analysis for overall survival. All other studies in the
tiragolumab programme will continue as planned.
The interim results for the primary endpoint of overall survival
were not mature at the time of the second interim analysis, with
median overall survival estimates of 22.9 months [95% CI: 17.5, NE]
in the tiragolumab plus Tecentriq arm, and 16.7 months [95% CI:
14.6, 20.2] in the Tecentriq monotherapy arm, yielding a hazard
ratio (HR) of 0.81 [95% CI: 0.63, 1.03]. This second interim
analysis took place in February 2023 and was based on a data
cut-off in November 2022, with a median follow-up of 15.5 months.
The data showed that tiragolumab plus Tecentriq was well-tolerated
and no new safety signals were identified when adding tiragolumab
to Tecentriq.
About the SKYSCRAPER-01 studySKYSCRAPER-01 is a
global Phase III, randomised double-blinded study evaluating
tiragolumab plus Tecentriq® (atezolizumab) versus Tecentriq alone
in 534 patients with first-line PD-L1-high locally advanced,
unresectable or metastatic non-small cell lung cancer. Patients
were randomised 1:1 to receive either tiragolumab plus Tecentriq or
placebo plus Tecentriq, until disease progression, loss of clinical
benefit or unacceptable toxicity. Co-primary endpoints are overall
survival (OS) and progression-free survival (PFS) in the primary
analysis set.
About tiragolumabTiragolumab
is a novel immune checkpoint inhibitor with an intact Fc region.
Tiragolumab selectively binds to TIGIT, a novel inhibitory immune
checkpoint, which suppresses the immune response to cancer. Based
on preclinical research, tiragolumab is thought to work as an
immune amplifier with other cancer immunotherapies such as
Tecentriq® (atezolizumab). The TIGIT pathway is distinct, but
complementary to the PD-L1/PD-1 pathway. Dual blockade with
tiragolumab and Tecentriq may help overcome immune suppression and
restore the immune response.
About Tecentriq®
(atezolizumab)Tecentriq
is a monoclonal antibody designed to bind with a protein called
PD-L1. Tecentriq is designed to bind to PD-L1 expressed on tumour
cells and tumour-infiltrating immune cells, blocking its
interactions with both PD-1 and B7.1 receptors. By inhibiting
PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq
may also affect normal cells.
About Roche Founded in 1896 in Basel,
Switzerland, as one of the first industrial manufacturers of
branded medicines, Roche has grown into the world’s largest
biotechnology company and the global leader in in-vitro
diagnostics. The company pursues scientific excellence to discover
and develop medicines and diagnostics for improving and saving the
lives of people around the world. We are a pioneer in personalised
healthcare and want to further transform how healthcare is
delivered to have an even greater impact. To provide the best care
for each person we partner with many stakeholders and combine our
strengths in Diagnostics and Pharma with data insights from the
clinical practice.
In recognising our endeavour to pursue a long-term perspective
in all we do, Roche has been named one of the most sustainable
companies in the pharmaceuticals industry by the Dow Jones
Sustainability Indices for the thirteenth consecutive year. This
distinction also reflects our efforts to improve access to
healthcare together with local partners in every country we
work.
Genentech, in the United States, is a wholly owned member of the
Roche Group. Roche is the majority shareholder in Chugai
Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected
by law.
Roche Group Media RelationsPhone: +41 61 688
8888 / e-mail: media.relations@roche.com
Hans Trees, PhDPhone: +41 79 407
72 58 |
Nathalie AltermattPhone: +41 79
771 05 25 |
Karsten KleinePhone: +41 79 461
86 83 |
Nina MählitzPhone: +41 79 327 54
74 |
Kirti PandeyPhone: +49 172
6367262 |
Rebekka SchnellPhone: +41 79 205
27 03 |
|
|
Sileia UrechPhone: +41 79 935 81
48 |
|
Roche Investor Relations
Dr.
Bruno EschliPhone: +41 61 68-75284
e-mail: bruno.eschli@roche.com |
Dr.
Sabine BorngräberPhone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com |
Dr.
Birgit MasjostPhone: +41 61
68-84814e-mail: birgit.masjost@roche.com |
Dr.
Gerard Tobin Phone: +41 61 68-72942 e-mail:
gerard.tobin@roche.com |
Investor Relations North America
Loren
KalmPhone: +1 650 225 3217 e-mail:
kalm.loren@gene.com |
- 23082023_MR_Phase III Skyscraper-01 study_en
Roche (LSE:0QQ6)
過去 株価チャート
から 4 2024 まで 5 2024
Roche (LSE:0QQ6)
過去 株価チャート
から 5 2023 まで 5 2024